Psychedelic Sector Insights

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond.

PSYCHEDELIC ALPHA

An Introduction to the Psychedelic Renaissance

40% of American adults report struggling with mental health or substance abuse disorders. Psychedelics may provide solutions to the global mental health and wellbeing crisis.

After decades of repression, psychedelic research is thriving.

Promising research has already resulted in FDA Breakthrough Therapy designations for psilocybin-assisted therapies aimed at treating depression, and MDMA-assisted psychotherapy for PTSD. Research on other ‘psychedelics’, including MDMA and LSD, is picking up pace with research centres at prestigious institutions—including Johns Hopkins and Imperial College London—driving a new wave of psychedelic research.

Decriminalisation and legalisation campaigns are succeeding.

In 2020 U.S. state of Oregon voted to decriminalise psychedelics and legalise Psilocybin Therapy. Washington, D.C., home of the White House, also decriminalised psychedelics, with many other states and localities poised to follow suit. Canada’s Health Minister has granted exemptions to allow access to psilocybin-assisted psychotherapy, setting precedent for future efforts to expand access.

Significant clinical trial milestones on the horizon.

In a Phase 3 MDMA-assisted therapy for PTSD trial that published last year, 88% of participants responded to the treatment. The trial’s sponsor, MAPS, expects to seek FDA approval as early as 2023. Multiple trials of psilocybin for depression are in Phase 2 or entering Phase 3, and are indicating preliminary safety and efficacy.

Psychedelics have the potential to address depression anxiety addiction PTSD chronic pain

Welcome to the Psychedelic Renaissance.

The Psychedelic Renaissance in Context

Today’s psychedelic renaissance benefits from a rich legacy of psychedelic research and usage dating back to pre-historic times.

The extensive psychedelic research and experimentation of the 1950s and ’60s represents a significant endowment, with today’s researchers taking up the torch.

1943

Albert Hofmann intentionally ingests LSD, experiencing the effects while cycling home. “Bicycle Day” is coined.

mid 1960s – 1971

Psychedelics criminalised, with Nixon declaring a War on Drugs in 1971 and a UN Convention following suit.

~10,000 BCE

Psychedelic iconography, such as mushrooms, appear in etched murals dating 10,000 BCE.

1950s and ’60s

Fertile decades for psychedelics research and experimentation, particularly in the U.S.

21st Century

Psychedelic renaissance emerges, with a return to human studies of psychedelics and decriminalisation campaigns.

Our Latest Analysis

Psychedelic Bulletin #114 – Lawsuit Alleges Compass Stole Trade Secrets; MindMed CMO Turns Activist Shareholder; California Decrim. Bill Tentatively Clears Hurdle

This week: we take a look at the lawsuit brought against Compass Pathways by Terran Biosciences; Compass says a tweet describing Terran as “slime” was due to a hack; former MindMed CMO turns activist shareholder; and more…

Psychedelic Bulletin #113 – Analysis of Company Spending Trends; Morgan Stanley Opine on Psychedelics; COMPASS Rallies

This week: our original analysis reveals psychedelics company spending trends; Morgan Stanley identifies psychedelics as disruptive theme; COMPASS Pathways rallies; and more…

Psychedelic Bulletin #112 – Inside the DEA Challenge; Second Psychedelics Company Enters Death Spiral Financing

This week: our latest Special Report goes inside the challenge to DEA’s proposed scheduling of 5 tryptamines; we take a look at the latest company to enter a ‘death spiral financing’; and more…

Receive Our Updates

Join our Newsletter

Psychedelic insights, commentary and analysis delivered to your inbox, including our weekly Bulletin.

Follow Us on Twitter

Join us on Twitter where we share the latest news and analysis, covering the entire psychedelic space.

Axios Logo
Business Insider logo grey
New York Times
Mother Jones Logo
Rolling Stone Logo
Finimize logo grey
Vice Logo